Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673673 · ClinicalTrials.gov registry record · Phase 2
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
A Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT00673673 is a Phase 2 study of Gastric Cancer and GastroEsophageal Cancer that has completed, run by Yale University. The registered enrollment target is 39 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00673673, a Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to determine the time to progression in patients treated with FOLFOX in combination with bevacizumab.
Conditions Studied
Interventions
- DRUG FOLFOX
- DRUG bevacizumab
Study Locations (2)
Connecticut
- Medical Oncology & Hematology PC - Hamden
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673673
The ClinicalTrials.gov registry entry for NCT00673673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which FOLFOX is the first listed.
NCT00673673 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00673673 about?
NCT00673673 is a clinical study titled "FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer". This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to determine the time to progression in p...
What is the current status of trial NCT00673673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2008-05. Estimated completion is 2014-07.
What conditions does trial NCT00673673 study?
This clinical trial studies the following conditions: Gastric Cancer, GastroEsophageal Cancer.
What interventions are being tested in trial NCT00673673?
The interventions under investigation include: FOLFOX (DRUG), bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00673673?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00673673 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.